Enliven Therapeutics, Inc.

ELVN
$52.95 (+ $0.14 + 0.27%)
Last updated: 2026-07-24 22:06 UTC
ELVN Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS45249V1070
CUSIP45249V107
Market Price52.95
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.81
Market Cap$983.4M
Book Value8.03
Price to Book2.062
Beta0.52
52w High25.37
52w Low13.3
Next Earnings DateN/A

Enliven Therapeutics, Inc. trades under ticker ELVN on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US45249V1070, CUSIP 45249V107. Also searched as Enliven Therapeutics.

Related researchELVN stock priceELVN share price45249V107Enliven Therapeutics stockEnliven Therapeutics share price
About the Company
Enliven Therapeutics Inc. is a biotechnology company dedicated to the development of novel therapeutic solutions targeting specific diseases. The primary focus of the company lies in advancing the field of precision medicine, which aims to tailor medical treatment to the individual characteristics of each patient, enhancing treatment efficacy and minimizing side effects. Enliven Therapeutics Inc. is actively engaged in researching and developing targeted therapies that address unmet medical needs across various therapeutic areas, particularly concentrating on genetic disorders and oncology. By leveraging cutting-edge technology platforms and innovative research methodologies, Enliven Therapeutics seeks to offer groundbreaking treatments that have a significant impact on patient care and outcomes. The company plays a vital role in the pharmaceutical and healthcare sectors, contributing to the rapid evolution of personalized healthcare solutions. In the financial market, Enliven Therapeutics represents an integral component of the biotechnology sector, often garnering interest from investors focused on emerging biotech innovations and their potential to transform traditional medical practices.
Price History